Market News / Story
TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot
Stocktwits ·
Stocktwits reports: NYSE-listed shares of Teva Pharmaceutical Industries (TEVA) rallied on Friday, touching fresh 52-week highs, after the company won U.S. FDA approval for a once-monthly schizophrenia injection, extending a strong year for the stock. TEVA stock rose as high as $42.02 and was up 6% at the time of writing. FDA Clears First Once-Monthly Olanzapine Shot The U.S. Food and Drug Administration approved Weltruza (olanzapine) for extended-release injectable suspension for adults…